Abbott Receives FDA Clearance for its Imaging Technology Using AI
Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) clearance for its latest optical coherence tomography (OCT) imaging platform powered by the company's new Ultreon Software. This innovative imaging software combines OCT with artificial intelligence (AI) to provide physicians an enhanced, comprehensive view of coronary blood flow and blockages to assist physician decision-making and provide the best pathway for treatment. 
Rapid integration of care services and secure data interchange has enabled Humber Teaching NHS Foundation Trust to embrace its EPR move to the cloud through Dedalus’ Healthcare Platform.
CSAM Health Group AS ("CSAM"), the leading provider of niche eHealth solutions in the Nordics, announced it has signed a contract with the five regions within the Danish health authority for CSAM’s Prosang blood, cell, and tissue management system for blood banks. In an agreement between CSAM and all five health regions, the new contract will translate to approximately NOK 75-100 million NOK over at the next six years and will be implemented in all blood banks in the country. 
Fujitsu in the UK has announced its support of the AWS for Health initiative from Amazon Web Services (AWS) by bringing Epic in the Cloud to NHS trusts and UK healthcare providers.
The access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. 
Exscientia has received a grant from the Bill & Melinda Gates Foundation and Gates Philanthropy Partners, as part of the COVID-19 Therapeutics Accelerator. This is to expedite the optimisation of a new class of COVID-19 therapeutics created using its artificial intelligence (AI) drug design platform.